Insulet (PODD) Reports In-Line Q2 EPS, FY Revenue Guidance Beats

Insulet (NASDAQ: PODD) reported Q2 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $109.8 million versus the consensus estimate of $106.17 million.

GUIDANCE:

Insulet sees Q3 2017 revenue of $112-116 million, versus the consensus of $110.4 million.

Insulet sees FY2017 revenue of $440-450 million, versus the consensus of $436.3 million.

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c